Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma

Haematologica

Volumn 90, Issue 1, 2005, Pages 78-85

  Martín, Alejandro ^a   Pérez Simón, José Antonio ^a   Caballero, Maria Dolores ^a   López Holgado, Natalia ^a   Vázquez, Lourdes ^a   Del Cañizo, Maria Consuelo ^a   San Miguel, Jesus F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Autologous transplantation; Bone marrow; Chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CARMUSTINE; CHLORMETHINE DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MELPHALAN; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; TIOGUANINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTERIAL INFECTION; BLEEDING; BLOOD TOXICITY; BONE MARROW CELL; CANCER CHEMOTHERAPY; CARDIOTOXICITY; FEMALE; FEVER; HUMAN; HUMAN CELL; LIVER TOXICITY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL; RETROSPECTIVE STUDY; STEM CELL; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BONE MARROW; BONE MARROW TRANSPLANTATION; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; CYTARABINE; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 13244267307     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin' disease: results of a BNLI randomised trial. Lancet 1993;341:105-1-4.
2. Schouten HC, Qian W, Kvaloy S, Porcellini A, Haeberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-27.
3. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
4. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001;19:1395-404.
5. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71.
6. Caballero MD, Perez-Simon JA, Iriondo A, Lahuerta JJ, Sierra J, Marin J, et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GELTAMO Spanish Cooperative Group. Ann Oncol 2003;14:140-51.
7. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996;347:353.
8. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, et al. Economic analysis of a randomised clinical trial to compare filgrastim-mobilised peripheral-blood-progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997;15:5-10.
9. Vose JM, Sharp G, Chan WC, Nichols C, Loh K, Inwards D, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002;20:2344-52.
10. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M, et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24:1279-83.
11. Lemoli RM, de Vivo A, Damiani D, Isidori A, Tani M, Bonini A, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 2003;102:1595-600.
12. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997;89:2233-58.
13. Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970-8.
14. Drake M, Ranaghan L, Morris TC, Nolan L, Desai ZR, Irvine AE, et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997;98:745-9.
15. Ketterer N, Sonet A, Dumontet C, Moullet I, Thieblemont C, Espinouse D, et al. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution. Bone Marrow Transplant 1999;23:1309-15.
16. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999;23:9-13.
17. Canales MA, Fernandez-Jimenez MC, Martin A, Arrieta R, Caballero MD, Diez J, et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001;86:494-8.
18. Martin A, Perez-Simon JA, Caballero MD, Lopez N, Garcia-Sanz R, Vazquez L, et al. Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. Bone Marrow Transplant 2004;33:579-87.
19. Visani G, Dinota A, Verlicchi F, Bandini G, Ricci P, Motta MR, et al. Autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma: comparison of different parameters in predicting the kinetics of haematological recovery. Bone Marrow Transplant 1988;3:599-605.
20. Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A. Analysis of factors affecting hematopoietic recovery after autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1990;6:291-4.
21. Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D, et al. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992;81:197-202.
22. Rabinowe SN, Neuberg D, Bierman PJ, Vose JM, Nemunaitis J, Singer JW, et al. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993;81:1903-8.
23. Iscove N, Senn JS, Till JE, McCulloch EA. Colony formation by normal and leukemic human bone marrow cells in culture: effect of conditioned medium from human leukocytes. Blood 1971;37:1-5.
24. Caballero MD, Rubio V, Rifon C, Heras I, García-Sanz R, Vázquez L, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplantation 1997;20:451-8.
25. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-31.
26. Dercksen MW, Rodenhuis S, Dirkson MK, Schaasberg WP, Baars JW, van der Wall E, et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995;13:1922-32.
27. Krause DS, Fackler MJ, Civin CI, May WS. CD34: Structure, biology, and clinical utility. Blood 1996;87:1-13.
28. Pecora AL, Preti RA, Gleim GW, Jennis A, Zahos K, Cantwell S, et al. CD34+ CD33rcells influence days to engraftment and tmsfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998;16:2093-104.
29. Meldgaard Knudsen L, Jensen L, Jarlbaek L, Hansen PG, Hansen SW, Drivsholm L, et al. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica 1999;84:517-24.
30. Menendez P, Caballero MD, Prosper F, Del Canizo MC, Perez-Simon JA, Mateos MV, et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 2002;42:1159-72.
31. Jones RJ, Celano P, Sharkis SJ, Sensenbrenner LL. Two phases of engraftment established by serial bone marrow transplantation in mice. Blood 1989;73:397-401.
32. To LB, Haylock DN, Dowse T, Simmons PJ, Trimboli S, Ashman LK, et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood 1994;84:2930-9.
33. Menedez P, Prosper F, Bueno C, Arbona C, San Miguel JF, Garcia-Conde J, et al. Sequential analysis of CD34+ and CD34rsubsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. Leukemia 2001;15:430-9.
34. Domenech J, Gihana E, Dayan A, Truglio D, Linassier C, Desbois I, et al. Haemopoiesis of transplanted patients with autologous marrows assessed by long-term marrow culture. Br J Haematol 1994;88:488-96.
35. del Canizo C, Lopez N, Caballero D, Fernandez E, Brufau A, Vazquez L, et al. Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:901-5.
36. Lopez-Holgado N, Garzon S, Martin A, Hermosin L, Campos R, Leon A. Hematopoietic abnormalities persist for more than six years after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma. Haematologica 2004;89:122-4.
37. Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-40.